Low CD30 Expression in Non-Hodgkin's Lymphoma Patients Does Not Predict Low Response to Brentuximab Vedotin – Consult QD
Q&A column
Blockade of tumor necrosis factor superfamily members CD30 and OX40 abrogates disease activity in murine immune-mediated glomerulonephritis - Kidney International
T-cells engineered to recognise tumours expressing the CD30 protein
Images from classic Hodgkin lymphoma, A. H&E, B. CD15, C. CD30, D. PAX5... | Download Scientific Diagram
Anti-CD30 , TNFRSF8 Antibody | CD30/412 | TNFRSF8
Colonic CD30 positive plasmablastic plasmacytoma masquerading as anaplastic large cell lymphoma - Pathology
Cureus | CD30-Positive Anaplastic Variant of Diffuse Large B-cell Lymphoma: Frequency and Association With Clinicopathological Parameters
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Br
PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus | Modern Pathology
Anti-CD30 , TNFRSF8 Antibody | SPM609 | TNFRSF8
CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). | Semantic Scholar
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features | Haematologica
Mohamed Salama, M.D., Discusses CD30 as a Predictive Marker for Therapy - Insights